论文部分内容阅读
目的利用Meta分析观察间歇性雄激素抑制疗法(IAD)治疗前列腺癌的疗效。方法检索PubMed、EMBASE、Cochrane-Library、万方、重庆维普和中国知网,纳入间歇性对比持续性雄激素抑制疗法(CAD)在前列腺癌治疗作用的随机对照试验(RCT),进行方法学质量评价,并采用RevMan 5.2软件进行统计学分析。结果19篇文献(共17个RCT)纳入研究。间歇性雄激素抑制疗法与持续性雄激素抑制治疗相比,在总生存期、肿瘤进展期、肿瘤特异性生存期方面差异均无统计学意义。在面部潮热、乳房胀痛增生、体力下降、头痛这4方面发病率低,而在转氨酶升高、勃起功能障碍、精神症状方面的发生率均无明显差异。结论间歇性雄激素抑制治疗可以作为治疗前列腺癌的有效方法,但仍需要进一步开展高质量、大样本的随机对照试验予以证实。
Objective To evaluate the efficacy of intermittent androgen deprivation therapy (IAD) in the treatment of prostate cancer by Meta-analysis. Methods PubMed, EMBASE, Cochrane Library, Wanfang, Chongqing Wipu and CNKI were enrolled in a randomized controlled trial (RCT) of intermittent contrast treatment of prostate cancer with continuous androgen suppression therapy (CAD) Evaluation, and use RevMan 5.2 software for statistical analysis. Results Nineteen articles (17 RCTs in total) were included in the study. Intermittent androgen suppression therapy compared with continuous androgen suppression therapy showed no significant differences in overall survival, tumor progression, tumor-specific survival. In the face of hot flashes, breast pain, hyperplasia, physical decline, headache, the incidence of these 4 low, but in the elevated transaminases, erectile dysfunction, the incidence of psychiatric symptoms were no significant differences. Conclusions Intermittent androgen suppression therapy may be an effective method for the treatment of prostate cancer. However, further randomized controlled trials of high quality and large samples are still needed.